Nectar Lifesciences Limited (NecLife) receives ANVISA approval for its Cephalosporin API’s manufacturing facility

New Delhi, June 01, 2015
Nectar Lifesciences Limited (NecLife) has received ANVISA cGMP (“Current Good Manufacturing Practices”) approval for its Cephalosporin API’s manufacturing facility. The National Health Surveillance Agency (in Portuguese, Agência Nacional de Vigilância Sanitária, ANVISA) is a regulatory body of the Brazilian government. Nectar has received approval for its Cephalosporin APIs’ manufacturing facility in Dera Bassi, Punjab. The regulatory authority concluded that the facility, systems and practices comply with ANVISA cGMP requirements. The facility is already approved by various international regulatory agencies such as US-FDA, MCC – South Africa, PMDA – Japan, OGYI-Hungary and KFDA- South Korea.

Nectar Lifesciences Limited (NecLife), the fast-growing manufacturer of generic pharmaceutical active pharmaceutical ingredients (APIs) and formulation products. NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 55 countries across five continents. NecLife has a global leadership position in 3 oral molecules and 2 sterile molecules. The company has 11 manufacturing facilities – eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife’s products include oral and sterile cephalosporin APIs, FDFs, empty hard gelatin capsules and Menthol and allied products.
IGMPI (www.igmpiindia.org )